Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hepatocellular Carcinoma
Interventions
Stereotactic Body Radiation Therapy (SBRT), Transcatheter Arterial Chemoembolization (TACE)
Radiation · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Conditions
Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
Interventions
DEB-TACE, Sorafenib
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Louisville, Kentucky + 3 more
Conditions
Carcinoma, Hepatocellular
Interventions
CyberKnife, TACE, CT Contrast, doxorubicin, Epirubicin, 5-fluorouracil, Mitomycin C, Gemcitabine, Cisplatin, SMANCS
Device · Procedure · Drug
Lead sponsor
Albert Koong
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Stanford, California
Conditions
Hepatocellular Carcinoma
Interventions
gadobenate dimeglumine (MultiHance)
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Hepatocellular Carcinoma
Interventions
Tocilizumab, Transcatheter Arterial Chemoembolization
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Not applicable Interventional Results available

Instylla HES Hypervascular Tumor Pivotal Study

NCT04523350
Conditions
Hypervascular Tumors
Interventions
Instylla HES, TAE or cTACE
Device · Other
Lead sponsor
Instylla, Inc.
Industry
Eligibility
22 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 9 more
Conditions
Carcinoma, Hepatocellular, Hepatobiliary Neoplasm, Liver Carcinoma
Interventions
TACE, SBRT
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Terminated No phase listed Observational

Prospective Tumor Response Evaluation

NCT02787954
Conditions
Hepatocellular Cancer, Metastatic Liver Cancer
Interventions
TACE, Y-90, MWA, IRE
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hepatocellular Carcinoma
Interventions
Lenvatinib, Transcatheter Arterial Chemoembolization
Drug · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Liver Cancer
Interventions
Lipiodol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib, TACE
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Stage IV Melanoma
Interventions
LC beads loaded with Doxorubicin
Device
Lead sponsor
Robert C. Martin
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Houston, Texas
Conditions
Hepatocellular Carcinoma
Interventions
Lumason
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania